Key Takeaways
- • Bill Ackman's Pershing Square Capital made a $65 billion bid to acquire Universal Music Group, proposing to relocate the company's listing from the Netherlands to New York and valuing the business at approximately €56 billion ($64.8 billion).
- • The Bolloré Group, a major shareholder in Universal Music Group, publicly urged the record label to reject Ackman's takeover offer, citing concerns that the acquisition poses "serious competition threats that are incompatible with the functioning of the internal market."
- • Bolloré's opposition represents a significant obstacle to the deal's progression, as the influential shareholder's public rejection signals resistance from a key institutional stakeholder with meaningful influence over UMG's strategic decisions.
- • The proposed transaction includes a US listing component as a strategic element, suggesting Ackman's pitch centered on enhancing shareholder value through improved market access and valuation multiples available in American capital markets.
Summary
However, the bid faced immediate and forceful opposition from the Bolloré Group, a substantial shareholder in Universal Music Group. On May 29, 2026, Bolloré's leadership publicly called on UMG to reject the Pershing Square offer, marking a critical rejection from an influential institutional investor. The shareholder's statement emphasized that the acquisition posed "serious competition threats that are incompatible with the functioning of the internal market," indicating that Bolloré views the deal as potentially damaging to market dynamics and competitive balance within the music industry.
Bolloré's public opposition presents a material headwind for the transaction's viability. As a major stakeholder with meaningful influence over UMG's board and strategic decisions, the group's rejection signals that consensus support for the deal may be difficult to achieve. The opposition reflects broader concerns about market concentration and competitive effects that may resonate with other institutional shareholders, regulators, or stakeholders evaluating the transaction's strategic merit and regulatory approval prospects.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.